Study record managers: refer to the Data Element Definitions if submitting registration or results information.
|1||NCT01566721||Active, not recruiting
|A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer||
||2577||All||18 Years and older (Adult, Older Adult)||NCT01566721||MO28048
|SafeHER||May 17, 2012||March 10, 2015||March 3, 2020||March 29, 2012||March 7, 2019||April 18, 2017||